title: New therapies: oral inhibitors and immune modulators.
abstract: Several new classes of antiviral drugs are undergoing development and should change the way that hepatitis C virus infection is treated in the future. It is likely that combinations of drugs that target different points in the viral replication and disease processes will prove most successful. It is hoped that such combinations will improve the efficacy, tolerability, and duration of antiviral treatment for this disease.
authors.affiliation: Division of Hepatology, Department of Medicine, Baylor University Medical Center, 4 Roberts, 3500 Gaston Avenue, Dallas, TX 75246, USA. garydav@baylorhealth.edu
authors.forename: Gary L
authors.initials: GL
authors.lastname: Davis
mesh_terms: D000914:Antibodies, Viral / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016174:Hepacivirus / Q000502:physiology*; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D010421:Pentanoic Acids / Q000494:pharmacology / Q000627:therapeutic use; D011741:Pyrimidine Nucleosides / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: C487112:3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid; D000914:Antibodies, Viral; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D009842:Oligopeptides; D010421:Pentanoic Acids; D011741:Pyrimidine Nucleosides; C486464:telaprevir; C506207:valopicitabine